Abbott Laboratories ABT (ABT) Had Its PT Cut by 3.85% at Jefferies & Co to $50.00; Shorts at Memorial Production Partners LP (MEMP) Raised By 13.94%

Memorial Production Partners LP (NASDAQ:MEMP) had an increase of 13.94% in short interest. MEMP’s SI was 1.40M shares in April as released by FINRA. Its up 13.94% from 1.23 million shares previously. With 1.32 million avg volume, 1 days are for Memorial Production Partners LP (NASDAQ:MEMP)’s short sellers to cover MEMP’s short positions. The SI to Memorial Production Partners LP’s float is 1.69%. The stock increased 1.56% or $0.002 on April 19, reaching $0.13. About shares traded. Memorial Production Partners LP (NASDAQ:MEMP) has declined 92.66% since September 13, 2016 and is downtrending. It has underperformed by 102.58% the S&P500.

Among 17 analysts covering Abbott Laboratories (NYSE:ABT), 9 have Buy rating, 0 Sell and 8 Hold. Therefore 53% are positive. Abbott Laboratories has $90 highest and $9 lowest target. $49.58’s average target is 13.79% above currents $43.57 stock price. Abbott Laboratories had 46 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Monday, January 4 by Morgan Stanley. On Friday, February 5 the stock rating was upgraded by Argus Research to “Buy”. The firm has “Buy” rating given on Tuesday, June 14 by Jefferies. Jefferies maintained Abbott Laboratories (NYSE:ABT) rating on Tuesday, September 13. Jefferies has “Buy” rating and $48 target. As per Saturday, August 29, the company rating was maintained by Deutsche Bank. Jefferies maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, July 14. Jefferies has “Buy” rating and $49 target. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Friday, January 29. RBC Capital Markets has “Outperform” rating and $45 target. Wells Fargo maintained Abbott Laboratories (NYSE:ABT) on Thursday, August 27 with “Buy” rating. As per Thursday, April 28, the company rating was downgraded by Piper Jaffray. As per Thursday, August 4, the company rating was maintained by Jefferies.

Since November 1, 2016, it had 6 buys, and 19 sales for $1.40 million activity. 3,851 Abbott Laboratories (NYSE:ABT) shares with value of $174,797 were sold by Warmuth Michael J. Another trade for 319 shares valued at $14,349 was made by NATH DEEPAK S. on Friday, February 17. $595,273 worth of Abbott Laboratories (NYSE:ABT) was sold by BIRD ROGER on Friday, February 17. 13,155 shares were sold by Contreras Jaime, worth $592,157. 51,892 shares were bought by WHITE MILES D, worth $2.10M on Thursday, November 10. Another trade for 12,775 shares valued at $499,345 was bought by Ford Robert B. Mason Heather L sold $86,068 worth of stock.

Investors sentiment increased to 1.01 in Q4 2016. Its up 0.05, from 0.96 in 2016Q3. It increased, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported. Bb&T Corp reported 478,337 shares. Colonial holds 0.81% of its portfolio in Abbott Laboratories (NYSE:ABT) for 65,084 shares. Glg Ltd Com owns 0.09% invested in Abbott Laboratories (NYSE:ABT) for 35,093 shares. Texas-based Academy Capital Mngmt Tx has invested 1.45% in Abbott Laboratories (NYSE:ABT). Scout Investments holds 0.02% or 18,600 shares in its portfolio. Goelzer Inv Mgmt invested in 0.03% or 5,672 shares. Meristem Llp holds 11,818 shares or 0.19% of its portfolio. Carret Asset Mgmt Ltd holds 0.45% or 61,389 shares. Columbia L L C Mngmt reported 0.24% stake. Reliance Tru Com Of Delaware has 0.11% invested in Abbott Laboratories (NYSE:ABT). Everpoint Asset Llc holds 0.35% in Abbott Laboratories (NYSE:ABT) or 490,000 shares. Woodmont Investment Counsel Ltd owns 45,854 shares or 0.51% of their US portfolio. American Comml Bank invested 0% of its portfolio in Abbott Laboratories (NYSE:ABT). Washington Mngmt stated it has 17,920 shares or 0.85% of all its holdings. Dsm Capital Prns Ltd invested in 122,702 shares or 0.08% of the stock.

About 200 shares traded. Abbott Laboratories (NYSE:ABT) has risen 7.26% since September 13, 2016 and is uptrending. It has underperformed by 2.67% the S&P500.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $75.53 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 60.88 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Memorial Production Partners LP owns, acquires and exploits oil and natural gas properties in North America. The company has market cap of $10.89 million. The Partnership is owned by its limited partners and general partner. It currently has negative earnings. The Company’s general partner is responsible for managing all of the Partnership’s activities and activities.

Among 14 analysts covering Memorial Production Partners (NASDAQ:MEMP), 0 have Buy rating, 6 Sell and 8 Hold. Therefore 0 are positive. Memorial Production Partners had 24 analyst reports since July 21, 2015 according to SRatingsIntel. Goldman Sachs downgraded Memorial Production Partners LP (NASDAQ:MEMP) on Friday, September 11 to “Sell” rating. On Wednesday, October 21 the stock rating was downgraded by Bank of America to “Neutral”. The stock has “Hold” rating by Wunderlich on Thursday, November 5. The stock of Memorial Production Partners LP (NASDAQ:MEMP) earned “Buy” rating by Wunderlich on Friday, October 9. Wells Fargo downgraded Memorial Production Partners LP (NASDAQ:MEMP) on Thursday, February 18 to “Underperform” rating. Citigroup downgraded Memorial Production Partners LP (NASDAQ:MEMP) rating on Monday, March 21. Citigroup has “Neutral” rating and $2.50 target. As per Wednesday, September 30, the company rating was maintained by Barclays Capital. On Wednesday, December 30 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. Citigroup maintained it with “Neutral” rating and $1.75 target in Thursday, September 29 report. Raymond James downgraded the stock to “Underperform” rating in Friday, October 21 report.

Investors sentiment decreased to 0.47 in 2016 Q4. Its down 0.05, from 0.52 in 2016Q3. It turned negative, as 17 investors sold Memorial Production Partners LP shares while 17 reduced holdings. 9 funds opened positions while 7 raised stakes. 4.21 million shares or 31.52% less from 6.15 million shares in 2016Q3 were reported. 700 are owned by Security National Company. Morgan Stanley reported 695,657 shares. Creative Planning reported 0% of its portfolio in Memorial Production Partners LP (NASDAQ:MEMP). Jpmorgan Chase reported 1,000 shares. Financial Bank Of America Corporation De reported 147,707 shares. Ims Management invested 0.02% in Memorial Production Partners LP (NASDAQ:MEMP). California Employees Retirement System holds 0% in Memorial Production Partners LP (NASDAQ:MEMP) or 59,500 shares. Stephens Ar reported 0% in Memorial Production Partners LP (NASDAQ:MEMP). Salient Cap Advsr Ltd Company holds 0% or 13,624 shares in its portfolio. Eubel Brady & Suttman Asset holds 10,000 shares. Akanthos Capital Management Ltd Com owns 1.00M shares. 2,000 were accumulated by Bessemer Grp Incorporated. Raymond James & Associates invested 0% of its portfolio in Memorial Production Partners LP (NASDAQ:MEMP). Rothschild Inv Corp Il invested in 0% or 17,550 shares. Thrivent Financial For Lutherans reported 0% of its portfolio in Memorial Production Partners LP (NASDAQ:MEMP).